Clinical Trial Site
Houston, Texas, United States
587 recruiting
Showing 1–20 of 45 trials
Recruiting
Phase 2Phase 3
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
Prosthetic joint infection
Peptilogics240 enrolled13 locationsNCT07214311
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled995 locationsNCT07181109
Recruiting
Phase 2
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
Von Willebrand Disease (vWD)Heavy Menstrual Bleeding (HMB)
Alnylam Pharmaceuticals24 enrolledNCT07575308
Recruiting
Phase 1
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
Healthy Volunteers
Alnylam Pharmaceuticals44 enrolled1 locationNCT07535606
Recruiting
Phase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,750 enrolled240 locationsNCT07052903
Recruiting
Phase 2
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM)
Alnylam Pharmaceuticals24 enrolled1 locationNCT07465224
Recruiting
Phase 1
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
Healthy Volunteers
Alnylam Pharmaceuticals76 enrolled1 locationNCT07295717
Recruiting
Phase 1Phase 2
A Study to Evaluate ALN-2232 in Participants With Obesity
Obesity
Alnylam Pharmaceuticals156 enrolled1 locationNCT07463846
Recruiting
Phase 3
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PN
Alnylam Pharmaceuticals125 enrolled41 locationsNCT07223203
Recruiting
Phase 1
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
Huntington’s Disease
Alnylam Pharmaceuticals66 enrolled19 locationsNCT06585449
Recruiting
Phase 2
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
Hypertension
Alnylam Pharmaceuticals93 enrolled3 locationsNCT07553442
Recruiting
Phase 1
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
Alzheimer s Disease
Alnylam Pharmaceuticals50 enrolled13 locationsNCT07214727
Recruiting
Phase 1
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Early-Onset Alzheimer Disease
Alnylam Pharmaceuticals60 enrolled8 locationsNCT05231785
Recruiting
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Transthyretin-Mediated AmyloidosisATTR Amyloidosis
Alnylam Pharmaceuticals1,500 enrolled40 locationsNCT04561518
Recruiting
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals2,000 enrolled4 locationsNCT07358078
Recruiting
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
Acute Hepatic Porphyria
Alnylam Pharmaceuticals150 enrolled30 locationsNCT04883905
Recruiting
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
PolyneuropathyHereditary Transthyretin-mediated (hATTR) Amyloidosis
Alnylam Pharmaceuticals10 enrolled7 locationsNCT05040373
Recruiting
Phase 1
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.329 enrolled17 locationsNCT06393738
Recruiting
Phase 2
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Alnylam Pharmaceuticals58 enrolledNCT07636811
Recruiting
Phase 1
A Study to Evaluate ALN-6222 in Participants With Obesity
Obesity
Alnylam Pharmaceuticals88 enrolled1 locationNCT07624071